華潤醫藥(03320.HK)委任白曉松為首席執行官
格隆匯1月14日丨華潤醫藥(03320.HK)公吿,為符合上市規則附錄十四所載企業管治守則條文第C.2.1條主席及首席執行官的角色應有區分,並不應由一人同時兼任的規定,及以便投放更多時間專注批准及監督集團的策略及政策,韓躍偉先生已辭任並不再擔任公司首席執行官、執行委員會主席、企業管治委員會成員及授權代表,並調任為公司非執行董事及將繼續出任董事會主席及公司提名委員會主席職務。
白曉松先生,已獲委任為公司執行董事、首席執行官、執行委員會主席、企業管治委員會成員及授權代表;青美平措先生因其他工作安排辭任公司非執行董事及審計委員會成員;及焦瑞芳女士獲委任為公司非執行董事及審計委員會成員,自2022年1月14日起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.